Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)

被引：0
|
作者：
Hughes, Derralynn [1 ]
Wilcox, William [2 ]
Hopkin, Robert J. [3 ]
Ganesh, Jaya [4 ]
Bernat, John [5 ]
Goker-Alpan, Ozlem [6 ]
Nicholls, Kathy [7 ]
Deegan, Patrick [8 ]
Pahl, Madeleine [9 ]
Whitley, Chester B. [10 ]
Chen, Michael
Cao, Liching
Schreeb, Katharina H.
机构：
[1] Royal Free London Hosp, London, England
[2] Emory Univ, Sch Med, Atlanta, GA USA
[3] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA
[4] Icahn Sch Med Mt Sinai, New York, NY USA
[5] Univ Iowa, Iowa City, IA USA
[6] Lysosomal & Rare Disorders Res & Treatment Ctr, Fairfax, VA USA
[7] Addenbrookes Hosp, Cambridge, England
[8] Univ Calif Irvine, Irvine, CA USA
[9] Univ Minnesota, Minneapolis, MN USA
[10] Sangamo Therapeut Inc, Richmond, CA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2025年 / 144卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2024.108773
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
146
引用
收藏
页数：2
相关论文
共 50 条
  • [21] LENTIVIRAL-MEDIATED GENE THERAPY FOR SEVERE PYRUVATE KINASE DEFICIENCY: RESULTS FROM AN ONGOING GLOBAL PHASE 1 STUDY
    Lopez Lorenzo, Jose Luis
    Shah, Ami
    Sevilla, Julian
    Navarro, Susana
    Llanos, Lucia
    de Camino Gaisse, Begona Perez
    Sanchez, Sol
    Zubicaray, Josune
    Glader, Bertil
    Chien, May
    Quintana Bustamante, Oscar
    Zeini, Miriam
    Choi, Grace
    Nicoletti, Eileen
    Rao, Gayatri
    Roncarolo, Maria Grazia
    Bueren, Juan
    Schwartz, Jonathan
    Carlos Segovia, Jose
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 275 - 276
  • [22] Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study
    Kanter, Julie
    Tisdale, John F.
    Mapara, Markus Y.
    Kwiatkowski, Janet L.
    Krishnamurti, Lakshmanan
    Schmidt, Manfred
    Miller, Alexandra L.
    Pierciey, Francis J., Jr.
    Huang, Wenmei
    Ribeil, Jean-Antoine
    Thompson, Alexis A.
    Walters, Mark C.
    BLOOD, 2019, 134
  • [23] Resolution of sickle cell disease manifestations in patients treated with LentiGlobin gene therapy: updated results from the phase 1/2 HGB-206 Group C study
    Asmal, M.
    Kanter, J.
    Tisdale, J. F.
    Mapara, M. Y.
    Kwiatkowski, J. L.
    Krishnamurti, L.
    Schmidt, M.
    Miller, A. L.
    Pierciey, F. J., Jr.
    Huang, W.
    Ribeil, J. -A.
    Thompson, A. A.
    Walters, M. C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 33 - 33
  • [24] PRX-102 for treating Fabry disease: immunogenicity and PK results from a phase 1-2 study
    Warnock, David
    Hughes, Derralynn
    Boyd, Simeon
    Giraldo, Pilar
    Gonzalez, Derlis
    Holida, Myrl
    Goker-Alpan, Ozlem
    Maegawa, Gustavo
    Atta, Mohamed
    Nicholls, Kathy
    Schiffmann, Raphael
    Tuffaha, Ahmad
    Charney, Martha
    Chertkoff, Raul
    Alon, Sari
    Brill-Almon, Einat
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S137 - S138
  • [25] Resolution of Sickle Cell Disease (SCD) Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 HGB-206 Group C Study
    Tisdale, John F.
    Kanter, Julie
    Mapara, Markus Y.
    Kwiatkowski, Janet L.
    Krishnamurti, Lakshmanan
    Schmidt, Manfred
    Miller, Alexandra L.
    Pierciey, Francis J., Jr.
    Huang, Wenmei
    Ribeil, Jean-Antoine
    Thompson, Alexis A.
    Walters, Mark C.
    MOLECULAR THERAPY, 2020, 28 (04) : 553 - 553
  • [26] Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease
    Mulan Deng
    Hongyu Zhou
    Shaomei He
    Haoheng Qiu
    Yanping Wang
    April Yuanyi Zhao
    Yunping Mu
    Fanghong Li
    Allan Zijian Zhao
    Orphanet Journal of Rare Diseases, 18
  • [27] Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease
    Deng, Mulan
    Zhou, Hongyu
    He, Shaomei
    Qiu, Haoheng
    Wang, Yanping
    Zhao, April Yuanyi
    Mu, Yunping
    Li, Fanghong
    Zhao, Allan Zijian
    ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)
  • [28] Intraputaminal AADC gene therapy for Parkinson's disease: Results of a phase 1 study
    Aminoff, M. J.
    Christine, C. W.
    Starr, P. A.
    Larson, P. S.
    Eberling, J. L.
    Jagust, W. J.
    Hawkins, R. A.
    VanBrocklin, H. F.
    Bankiewicz, K. S.
    MOVEMENT DISORDERS, 2009, 24 : S254 - S255
  • [29] Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1 (GD1): Updated Phase 2 Results
    Peterschmitt, M. Judith
    Lukina, Elena
    Watman, Nora
    Dragosky, Marta
    Lastrebner, Marcelo
    Pastores, Gregory
    Avila Arreguin, Elsa
    Phillips, Mici
    Rosenbaum, Hanna
    Sysoeva, Elena
    Aguzzi, Rasha
    Ross, Leorah
    Puga, Ana Cristina
    MOLECULAR GENETICS AND METABOLISM, 2012, 105 (02) : S52 - S52
  • [30] Changing the Treatment Paradigm for Pyruvate Kinase Deficiency with Lentiviral Mediated Gene Therapy: Interim Results from an Ongoing Global Phase 1 Study
    Shah, A. J.
    Lopez Lorenzo, J. L.
    Navarro, S.
    Sevilla, J.
    Llanos, L.
    de Camino Gaisse, B. Perez
    Sanchez, S.
    Glader, B.
    Chien, M.
    Quintana Bustamante, O.
    Zeini, M.
    Choi, G.
    Nicoletti, E.
    Rao, G. R.
    Roncarolo, M. G.
    Bueren, J. A.
    Schwartz, J. D.
    Segovia, J. C.
    MOLECULAR THERAPY, 2022, 30 (04) : 170 - 170
12345